{"entity":{"type":"insider","cik":"0001861120","url":"/insider/0001861120","json_url":"/insider/0001861120.json","name":"Schneeberger Daniel","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":10,"first":"2025-04-11","last":"2026-08-03","span_basis":"filed_date"},"name_variants":[{"name":"Schneeberger Daniel","source":"filing","n_filings":10,"first_seen":"2025-04-11","last_seen":"2026-08-03"}],"transactions":[{"id":6009913,"accession":"0001940272-26-000013","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001940272-26-000013","line_url":"/filing/0001940272-26-000013","is_derivative":false,"issuer_cik":"0001661059","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001661059","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":36303.0,"shares_display":"36,303","price_per_share":4.941039032586839,"price_display":"4.94","price_state":"stated","total_value":179374.54,"total_display":"179,374.54","total_whole":"179,375","shares_owned_after":714416.0,"shares_owned_after_display":"714,416","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-31","filed_date":"2026-08-03","scope":"insider","n_lines":3},{"id":6009905,"accession":"0001940272-26-000013","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001940272-26-000013","line_url":"/filing/0001940272-26-000013","is_derivative":false,"issuer_cik":"0001661059","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001661059","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":292850.0,"shares_display":"292,850","price_per_share":4.93339921461499,"price_display":"4.93","price_state":"stated","total_value":1444745.96,"total_display":"1,444,745.96","total_whole":"1,444,746","shares_owned_after":608266.0,"shares_owned_after_display":"608,266","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-08-03","scope":"insider","n_lines":6},{"id":5806909,"accession":"0001940272-26-000012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001940272-26-000012","line_url":"/filing/0001940272-26-000012","is_derivative":false,"issuer_cik":"0001661059","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001661059","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3410.0,"shares_display":"3,410","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":17050.0,"total_display":"17,050.00","total_whole":"17,050","shares_owned_after":391666.0,"shares_owned_after_display":"391,666","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-29","filed_date":"2026-07-29","scope":"insider","n_lines":2},{"id":5806904,"accession":"0001940272-26-000012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001940272-26-000012","line_url":"/filing/0001940272-26-000012#line-2","is_derivative":false,"issuer_cik":"0001661059","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001661059","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6400.0,"shares_display":"6,400","price_per_share":4.9496,"price_display":"4.95","price_state":"stated","total_value":31677.44,"total_display":"31,677.44","total_whole":"31,677","shares_owned_after":389856.0,"shares_owned_after_display":"389,856","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-28","filed_date":"2026-07-29","scope":"insider"},{"id":5806902,"accession":"0001940272-26-000012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001940272-26-000012","line_url":"/filing/0001940272-26-000012#line-1","is_derivative":false,"issuer_cik":"0001661059","issuer_name":"NextCure, Inc.","issuer_ticker":"NXTC","issuer_name_source":null,"issuer_url":"/issuer/0001661059","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7798.0,"shares_display":"7,798","price_per_share":4.9994,"price_display":"5.00","price_state":"stated","total_value":38985.3212,"total_display":"38,985.32","total_whole":"38,985","shares_owned_after":383456.0,"shares_owned_after_display":"383,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-27","filed_date":"2026-07-29","scope":"insider"},{"id":5866292,"accession":"0001940272-26-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001940272-26-000010","line_url":"/filing/0001940272-26-000010#line-1","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Schneeberger Daniel; ADAR1 Capital Management, LLC","owner_display_name":"Schneeberger Daniel","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.555,"price_display":"1.56","price_state":"stated","total_value":1555.0,"total_display":"1,555.00","total_whole":"1,555","shares_owned_after":801000.0,"shares_owned_after_display":"801,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-15","filed_date":"2026-07-17","scope":"insider"},{"id":6192671,"accession":"0001104659-26-064729","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-064729","line_url":"/filing/0001104659-26-064729","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"Schneeberger Daniel; ADAR1 Capital Management, LLC","owner_display_name":"Schneeberger Daniel","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10200.0,"shares_display":"10,200","price_per_share":13.978627450980392,"price_display":"13.98","price_state":"stated","total_value":142582.0,"total_display":"142,582.00","total_whole":"142,582","shares_owned_after":926152.0,"shares_owned_after_display":"926,152","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-19","filed_date":"2026-05-20","scope":"insider","n_lines":2},{"id":6182000,"accession":"0001940272-26-000008","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001940272-26-000008","line_url":"/filing/0001940272-26-000008","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":468551.0,"shares_display":"468,551","price_per_share":1.5399559275297674,"price_display":"1.54","price_state":"stated","total_value":721547.8898,"total_display":"721,547.89","total_whole":"721,548","shares_owned_after":600000.0,"shares_owned_after_display":"600,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-19","filed_date":"2026-05-21","scope":"insider","n_lines":3},{"id":6192663,"accession":"0001104659-26-064729","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-064729","line_url":"/filing/0001104659-26-064729#line-1","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"Schneeberger Daniel; ADAR1 Capital Management, LLC","owner_display_name":"Schneeberger Daniel","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6009.0,"shares_display":"6,009","price_per_share":13.9759,"price_display":"13.98","price_state":"stated","total_value":83981.1831,"total_display":"83,981.18","total_whole":"83,981","shares_owned_after":916152.0,"shares_owned_after_display":"916,152","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-20","scope":"insider"},{"id":5869552,"accession":"0001104659-26-062883","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-26-062883","line_url":"/filing/0001104659-26-062883","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":13.9,"price_display":"13.90","price_state":"stated","total_value":4170.0,"total_display":"4,170.00","total_whole":"4,170","shares_owned_after":910143.0,"shares_owned_after_display":"910,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-15","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":5869548,"accession":"0001104659-26-062883","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-062883","line_url":"/filing/0001104659-26-062883","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":79259.0,"shares_display":"79,259","price_per_share":13.989666073253511,"price_display":"13.99","price_state":"stated","total_value":1108806.9433,"total_display":"1,108,806.94","total_whole":"1,108,807","shares_owned_after":909843.0,"shares_owned_after_display":"909,843","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-13","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":6192636,"accession":"0001104659-26-060513","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-26-060513","line_url":"/filing/0001104659-26-060513#line-4","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800.0,"shares_display":"800","price_per_share":13.8288,"price_display":"13.83","price_state":"stated","total_value":11063.04,"total_display":"11,063.04","total_whole":"11,063","shares_owned_after":830584.0,"shares_owned_after_display":"830,584","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-12","filed_date":"2026-05-13","scope":"insider"},{"id":6192632,"accession":"0001104659-26-060513","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-060513","line_url":"/filing/0001104659-26-060513","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":13.9998368,"price_display":"14.00","price_state":"stated","total_value":699991.84,"total_display":"699,991.84","total_whole":"699,992","shares_owned_after":809884.0,"shares_owned_after_display":"809,884","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-11","filed_date":"2026-05-13","scope":"insider","n_lines":3},{"id":6169015,"accession":"0001104659-26-056540","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-056540","line_url":"/filing/0001104659-26-056540#line-3","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35101.0,"shares_display":"35,101","price_per_share":13.9956,"price_display":"14.00","price_state":"stated","total_value":491259.5556,"total_display":"491,259.56","total_whole":"491,260","shares_owned_after":779784.0,"shares_owned_after_display":"779,784","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider"},{"id":6169014,"accession":"0001104659-26-056540","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-056540","line_url":"/filing/0001104659-26-056540","is_derivative":false,"issuer_cik":"0001739410","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001739410","owner_cik":null,"owner_name":"ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":120804.0,"shares_display":"120,804","price_per_share":13.968152975067051,"price_display":"13.97","price_state":"stated","total_value":1687408.752,"total_display":"1,687,408.75","total_whole":"1,687,409","shares_owned_after":744683.0,"shares_owned_after_display":"744,683","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-06","scope":"insider","n_lines":2},{"id":5189771,"accession":"0000902664-25-004411","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-004411","line_url":"/filing/0000902664-25-004411","is_derivative":false,"issuer_cik":"0001664710","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001664710","owner_cik":null,"owner_name":"ADAR1 Capital Management GP, LLC; ADAR1 Partners, LP; ADAR1 Capital Management, LLC; Schneeberger Daniel","owner_display_name":"ADAR1 Capital Management GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5389264.0,"shares_display":"5,389,264","price_per_share":17.75,"price_display":"17.75","price_state":"stated","total_value":95659436.0,"total_display":"95,659,436.00","total_whole":"95,659,436","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-15","filed_date":"2025-10-15","scope":"insider","n_lines":3},{"id":4029839,"accession":"0001104659-25-034321","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-25-034321","line_url":"/filing/0001104659-25-034321","is_derivative":false,"issuer_cik":"0001664710","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001664710","owner_cik":null,"owner_name":"Schneeberger Daniel; ADAR1 Capital Management GP, LLC; ADAR1 Capital Management, LLC; ADAR1 Partners, LP","owner_display_name":"Schneeberger Daniel","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":934258.0,"shares_display":"934,258","price_per_share":10.130512395933458,"price_display":"10.13","price_state":"stated","total_value":9464512.25,"total_display":"9,464,512.25","total_whole":"9,464,512","shares_owned_after":4318404.0,"shares_owned_after_display":"4,318,404","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-09","filed_date":"2025-04-11","scope":"insider","n_lines":5}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001661059","name":"NextCure, Inc.","url":"/issuer/0001661059","role":"Ten percent owner","n_filings":2,"first_seen":"2026-07-29","last_seen":"2026-08-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001728328","name":"InMed Pharmaceuticals Inc.","url":"/issuer/0001728328","role":"Ten percent owner","n_filings":2,"first_seen":"2026-05-21","last_seen":"2026-07-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Ten percent owner","n_filings":4,"first_seen":"2026-05-06","last_seen":"2026-05-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001664710","name":"Keros Therapeutics, Inc.","url":"/issuer/0001664710","role":"Ten percent owner","n_filings":2,"first_seen":"2025-04-11","last_seen":"2025-10-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001861120","retrieved_at":"2026-08-23T20:59:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}